← Issue №15/ week of Oct 11, 2026/Colorectal

Stromal biomarker-based framework for identifying pMMR/MSS and dMMR/MSI colorectal cancers with poor outcomes and limited benefit from immunotherapy.

From GI Signals issue №15: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Colorectal prospective cohort · n=3,000 · Oct 7, 2026 · Gut · IF 24.6

Stromal biomarker-based framework for identifying pMMR/MSS and dMMR/MSI colorectal cancers with poor outcomes and limited benefit from immunotherapy.

Basic sciencebiomarkerbasic sciencetranslationalcolorectal cancer
Clinical takeawayNo clinical action yet: a mechanistic finding in preclinical models and retrospective analyses. Consider CTHRC1(+) CAF assessment in future histopathological workflows pending prospective validation.
What it foundCTHRC1(+) CAFs identified in over 3000 CRC samples were linked to poor outcomes and resistance to immune checkpoint inhibitors (compared to standard immunotherapy) in both dMMR/MSI and pMMR/MSS tumours, particularly in stroma-rich, treatment-resistant tumours and pMMR/MSS with limited therapeutic options.
ContextChallenges current CRC stratification by identifying a stromal biomarker that predicts immunotherapy resistance and poor outcomes across mismatch repair statuses, particularly in stroma-rich, treatment-resistant tumours and pMMR/MSS with limited therapeutic options.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Iglesias Coma M … Calon A · Gut · IF 24.6 · PubMed ↗Permalink
← Read the whole of issue №15 Every paper GI Signals surfaces gets a page like this one. All issues